Abstract
There are growing numbers of patients who can receive hematopoietic stem cell transplantation with alternative donors, resulting in increasing numbers of patients complicated with chronic graft-versus-host disease (GVHD). However, the incidence of chronic GVHD among the Japanese population is lower than those reported from European and American countries. There is no effective prophylaxis for chronic GVHD and the secondary treatment for cases refractory to corticosteroids. Extensive clinical research to focus on chronic GVHD is required.
